VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+6.49%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$779M
AUM Growth
+$779M
(-5.6%)
Cap. Flow
-$14.1M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
71.03%
Holding
35
New
6
Increased
2
Reduced
6
Closed
9
Top Buys
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$44.9M |
| 2 |
Travere Therapeutics
TVTX
|
$42M |
| 3 |
Nuvalent
NUVL
|
$18.1M |
| 4 |
Corvus Pharmaceuticals
CRVS
|
$16.6M |
| 5 |
ATYR
aTyr Pharma
ATYR
|
$14.2M |
Top Sells
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$24.5M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$19.4M |
| 3 |
ESSA Pharma
EPIX
|
$17.9M |
| 4 |
RAPT Therapeutics
RAPT
|
$12.4M |
| 5 |
Kura Oncology
KURA
|
$12M |
Sector Composition
| 1 | Healthcare | 96.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viridian Therapeutics
VRDN
$1.59B
| $321K | 0.04% |
19,495
| – | – |
|
|
TRIL
27
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-2,001,686
| Closed | -$19.4M |
|
|
PRVB
28
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – |
-2,902,744
| Closed | -$24.5M |
|
|
HARP
29
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| – | – |
-512,005
| Closed | -$7.1M |
|
|
30
RAPT Therapeutics
RAPT
$187M
| – | – |
-391,000
| Closed | -$12.4M |
|
|
31
Kura Oncology
KURA
$732M
| – | – |
-575,000
| Closed | -$12M |
|
32
Keros Therapeutics
KROS
$640M
| – | – |
-272,306
| Closed | -$11.6M |
|
|
33
ESSA Pharma
EPIX
$11.2M
| – | – |
-625,754
| Closed | -$17.9M |
|
34
Aligos Therapeutics
ALGS
$75.1M
| – | – |
-408,377
| Closed | -$8.33M |
|
35
Adicet Bio
ACET
$60.8M
| – | – |
-183,702
| Closed | -$1.89M |
|